A recent study explores cognitive and affective predictors of exertion-related fatigue in patients with primary biliary cholangitis. This research contributes to understanding the psychosocial factors influencing fatigue in this patient population.

The Scottish Medicines Consortium has accepted Livdelzi for the treatment of primary biliary cholangitis, enhancing treatment options for patients suffering from chronic itch associated with the disease. This decision marks a significant step in addressing the unmet needs of this patient population.

A recent study establishes meaningful improvement thresholds for pruritus and sleep disturbance in primary biliary cholangitis (PBC) using the Worst Itch and Sleep Interference Numerical Rating Scales. This research provides valuable insights for assessing treatment efficacy in PBC patients.

A recent study published in PubMed examines real-world treatment patterns and clinical outcomes for patients with primary biliary cholangitis in the United States. The findings provide insights into the effectiveness of current therapies and patient management strategies.

The CHMP has recommended Lynavoy for EU approval as the first IBAT inhibitor targeting cholestatic pruritus in primary biliary cholangitis (PBC). This marks a significant advancement in treatment options for patients suffering from this rare condition.